Neovascular Age-Related Macular Degeneration (nAMD) is an eye condition that can cause vision loss. This study is testing a new treatment called OTX-TKI, which is an implant placed inside the eye. This implant contains a drug called Axitinib, which might help improve vision in people with nAMD.

To join this study, you should either be new to treatments for nAMD or have started with a specific treatment recently. You also need to be able to see a certain number of letters on a vision test. People with significant scarring or damage in their eyes cannot participate.

The study will check if the Axitinib implant is safe and if it helps treat nAMD. If you decide to take part, you will need to give your written consent.

• Study involves eye treatment with a new implant.
• Participants must meet certain vision and health criteria.
• Written consent is required to join the study.